SL VaxiGen Overview

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

SL VaxiGen General Information

Description

Operator of a clinical-stage research and development company intended to develop various vaccine therapeutics. The company has combined the disease-specific multiple antigens and applied antigen engineering technologies such as codon optimization and gene shuffling in an efficient expression vector system to induce antigen-specific strong and broad immunity, enabling healthcare providers to save lives by various innovative genetic and protein engineering technologies for infectious diseases and cancers.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 7 Floor, Building C, Korea Bio Park
  • Daewangpangyo-ro 700, Bundang-gu
  • Seongnam, Gyeonggi
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 7 Floor, Building C, Korea Bio Park
  • Daewangpangyo-ro 700, Bundang-gu
  • Seongnam, Gyeonggi
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SL VaxiGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 04-Jun-2025 Completed Out of Business
1. Seed Round 01-Jan-2008 Completed Startup
To view SL VaxiGen’s complete valuation and funding history, request access »

SL VaxiGen Patents

SL VaxiGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022131832-A1 Novel vaccine composition for prevention and treatment of coronavirus Inactive 16-Dec-2020
WO-2021201612-A1 Novel vaccine composition for prevention and treatment of coronavirus Inactive 31-Mar-2020
US-20200360514-A1 A novel vaccine adjuvant Active 02-Feb-2018
JP-2021512950-A Immune aids for new vaccines Pending 02-Feb-2018
WO-2019151760-A1 Novel multivalent hpv vaccine composition Inactive 02-Feb-2018 A61K39/12
To view SL VaxiGen’s complete patent history, request access »

SL VaxiGen FAQs

  • Where is SL VaxiGen headquartered?

    SL VaxiGen is headquartered in Seongnam, South Korea.

  • What industry is SL VaxiGen in?

    SL VaxiGen’s primary industry is Drug Discovery.

  • Is SL VaxiGen a private or public company?

    SL VaxiGen is a Private company.

  • What is SL VaxiGen’s current revenue?

    The current revenue for SL VaxiGen is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process